Phase I authorized. €10M Series A now open.
Lamina Therapeutics opens its Series A funding round of €10M to bring the world's first bone and cartilage regeneration solution to patients.
Lamina Therapeutics is proud to announce the opening of its €10M Series A funding round. Our flagship product, Lamina.One®, is the world's first combined Advanced Therapy Medicinal Product (cATMP) authorized by both the EMA and ANSM for a first-in-human Phase I clinical trial, simultaneously regenerating subchondral bone and cartilage in a single minimally invasive procedure. Today, over 500 million patients worldwide suffer from osteoarthritis with no curative treatment available. Lamina.One® was built to change that. In just 4 years from founding, our team has gone from early-stage IP to full clinical trial authorization, one of the fastest timelines in regenerative medicine. We are now raising €10 million to fund our European Phase I/II clinical trial and bring this breakthrough to the patients who need it most.
🌍 500M+ osteoarthritis patients worldwide
💶 €10M Series A now open
🏥 World first cATMP authorized by EMA & ANSM for isolated focal knee osteochondral lesions
⚡ 4 years from founding to clinical authorization
📄 3 patent families (EU, US & JP)
Interested in partnering or investing? Contact us at laminadpo@lamina.one
Related articles
-
Millions of Patients. No Real Cure. Until Now.
For millions of osteoarthritis patients, joint replacement is the only option left. Lamina Therapeutics is changing that, with the world's first implant that actually regenerates both bone and cartilage. EMA & ANSM authorized. Series A open.
-
Lamina Therapeutics obtient l approbation de l EMA et de l ANSM
Nous sommes ravis de partager avec vous une bonne nouvelle ! Lamina Therapeutics a officiellement reçu l'approbation de l'Agence Européenne des Médicaments European Medicines Agency (EMA) et de l'ANSM Agence nationale de sécurité du médicament et des produits de santé pour lancer son premier essai clinique de phase I chez l'homme pour l'arthrose du genou, qui se déroulera à Strasbourg. Cet essai marque une première mondiale dans la combinaison d'un dispositif médical implantable thérapeutique combiné à des cellules souches autologues (médicament de thérapie innovante MTI combiné) pour traiter l'arthrose avancée en régénérant à la fois l'os sous-chondral et le cartilage. Cette approche pionnière offre un espoir à des millions de patients dans le monde qui souffrent de cette maladie. Cette belle avancée est le résultat du dévouement de notre équipe de recherche strasbourgeoise. Il s'agit d'une belle réussite pour Lamina Therapeutics fondée par Nadia Benkirane-Jessel, mais aussi pour le laboratoire INSERM UMR1260 Nanomédecine Régénérative. Cette belle collaboration entre les membres de Lamina Therapeutics plus particulièrement le CEO Lemmens Stephan, Project Manager Rana Smaida et les membres de l’UMR1260 est le secret de cette réussite. INSERM-University of Strasbourg UMR1260 Nanomédecine régénérative et Spin-Off Lamina Therapeutics
-
Big News from Spin-off Lamina Therapeutics and INSERM-University of Strasbourg UMR1260 Regenerative Nanomedicine !
We are thrilled to announce that Lamina Therapeutics has received approval from the European Medicines Agency (EMA) and the ANSM Agence nationale de sécurité du médicament et des produits de santé to initiate our first-in-human Phase I clinical trial in knee osteoarthritis! This groundbreaking trial, which will take place in Strasbourg, France, represents a world first: combining a therapeutic implantable medical device with autologous stem cells (combined ATMP) to treat advanced osteoarthritis by regenerating both subchondral bone and cartilage. Osteoarthritis remains a major challenge for millions of patients worldwide, and we are excited to take a leading role in pioneering this innovative solution to restore joint function and improve quality of life. We are deeply grateful to our exceptional team (Rana Smaida, Lemmens Stephan, Nadia Benkirane-Jessel...), collaborators, and regulatory partners who have worked tirelessly to make this possible. We’re looking forward to sharing updates as we begin this exciting journey towards transforming osteoarthritis treatment.